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Background: Polioviruses are human pathogens and the causative agents of
poliomyelitis. Polioviruses are icosahedral single-stranded RNA viruses, which
belong to the picornavirus family, and occur as three distinct serotypes. All
three serotypes of poliovirus can infect primates, but only type 2 can infect
mice. The crystal structures of a type 1 and a type 3 poliovirus are already
known. Structural studies of poliovirus type 2 Lansing (PV2L) were initiated to
try to enhance our understanding of the differences in host range specificity,
antigenicity and receptor binding among the three serotypes of poliovirus.
Results:  The crystal structure of the mouse neurovirulent PV2L complexed with
a potent antiviral agent, SCH48973, was determined at 2.9 Å resolution.
Structural differences among the three poliovirus serotypes occur primarily in
the loop regions of the viral coat proteins (VPs), most notably in the loops of
VP1 that cluster near the fivefold axes of the capsid, where the BC loop of
PV2L is disordered. Unlike other known structures of enteroviruses, the entire
polypeptide chain of PV2L VP4 is visible in the electron density and RNA bases
are observed stacking with conserved aromatic residues (Tyr4020 and
Phe4046) of VP4. The broad-spectrum antiviral agent SCH48973 is observed
binding in a pocket within the b -barrel of VP1, in approximately the same
location that natural ‘pocket factors’ bind to polioviruses. SCH48973 forms
predominantly hydrophobic interactions with the pocket residues.
Conclusions: Some of the conformational changes required for infectivity and
involved in the control of capsid stability and neurovirulence in mice may occur
in the vicinity of the fivefold axis of the poliovirus, where there are significant
structural differences among the three poliovirus serotypes in the surface
exposed loops of VP1 (BC, DE, and HI). A surface depression is located at the
fivefold axis of PV2L that is not present in the other two poliovirus serotypes.
The observed interaction of RNA with VP4 supports the observation that loss of
VP4 ultimately leads to the loss of viral RNA. A model is proposed that
suggests dual involvement of the virion fivefold and pseudo-threefold axes in
receptor-mediated initiation of infection by picornaviruses.
Introduction
Poliovirus is a member of the picornavirus family and is
the causative agent of poliomyelitis. Polioviruses are
among the most extensively studied and characterized
animal viruses and serve as a paradigm for understanding
animal virus–host interactions. In spite of this, however,
many aspects of poliovirus biology remain incompletely
characterized.
Picornaviruses are small, spherical (~300Å in diameter)
non-enveloped (+)-strand RNA viruses [1]. The picor-
navirus family is subdivided into five genera: enteroviruses,
rhinoviruses, aphthoviruses, cardioviruses, and hepato-
viruses. Polioviruses are human enteroviruses, and like all
enteroviruses, are pH stable and survive passage through
the stomach and gut to the intestines where they replicate
[2]. The poliovirus capsid is composed of 60 copies of each
of four viral polypeptides designated VP1, VP2, VP3, and
VP4, that are arranged in an icosahedrally symmetric
manner. The virion encapsidates one copy of a 7.5kb mes-
senger RNA that is polyadenylated at the 3¢ terminus and
carries a small protein, VPg, covalently attached at the 5¢
end. The genomic RNA is monocistronic and encodes a
large polyprotein containing approximately 2,200 amino
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acid residues. Virus-encoded proteases, 2A, 3C, and 3CD,
carry out a series of cleavages to generate 11 protein prod-
ucts. Three of these products, VP0, VP1, and VP3, assem-
ble to make protomers, which in turn associate to form the
pentameric assembly intermediates that ultimately come
together to form the complete viral capsid. After assembly
of the viral capsid and RNA encapsidation, cleavage of VP0
into VP2 and VP4 leads to the formation of mature, infec-
tious virus particles. The structure of the poliovirus type 1
Mahoney (PV1M) empty capsid shows that the VP0 cleav-
age site is located on the interior of the viral capsid, suggest-
ing that the cleavage is autocatalytic, possibly mediated by
the capsid proteins and/or genomic RNA [3–5]. A large
increase in the stability of the virion is associated with the
cleavage of VP0, which is thought to ‘lock’ the virus particle
into a metastable state.
Unlike other members of the picornavirus family, such as
rhinoviruses (>100 serotypes) or coxsackieviruses (29
serotypes), polioviruses exist in only three serotypes. It has
been suggested that one reason for the occurrence of only
three serotypes of poliovirus is that the neutralizing anti-
genic sites (N-Ag sites) and receptor-binding sites overlap
[6]. All three serotypes of poliovirus are neurovirulent in
primates, but only poliovirus type 2 Lansing (PV2L) is
neurovirulent in mice when injected intracerebrally. 
The human poliovirus receptor (PVR) has been identified
as a member of the immunoglobulin superfamily and it
appears to be a determinant of the host range of
polioviruses [7,8]. The resistance of mice to infection by
type 1 and type 3 polioviruses is due to the lack of the
PVR; transgenic mice expressing the human PVR are sus-
ceptible to infection by all three serotypes of poliovirus
[9,10]. The determinants of type 1 and type 3 poliovirus
host restriction in mice have been studied extensively
[11–14]. One determinant of mouse adaptation was
mapped to the BC loop of VP1 (amino acids 94–102) [11].
Replacement of six amino acids of the VP1 BC loop of
PV1M by those of the PV2L strain yielded a chimeric
PV1M strain that was neurovirulent in mice [15]. The BC
loop of VP1 does not seem to be the only determinant of
the mouse neurovirulent phenotype, as other mutations in
the capsid region are capable of conferring this phenotype
to PV1M [12–14].
The binding of polioviruses to the PVR induces struc-
tural changes leading to the formation of altered or
‘A’ particles that have lost VP4, have portions of the
N terminus of VP1 externalized, and sediment at 135S,
as compared to 160S for the native virions [16,17]. For-
mation of A particles has been thought to be an oblig-
atory step in the infection of the cell [18], however,
a recent report contradicts this idea [19]. Formation of
A particles can be prevented by capsid-binding antiviral
agents [20–22]. 
Numerous antiviral agents have been synthesized that are
active against rhinoviruses and enteroviruses, including
polioviruses. Many of these antiviral agents have been
studied structurally in complexes with rhinoviruses,
polioviruses, and coxsackievirus B3 (CVB3) [23–32]. In all
cases, the antiviral agents bind in a hydrophobic pocket in
the b -barrel core of VP1. This pocket is located directly
beneath a prominent surface depression that circum-
scribes each of the fivefold axes of the virion. This depres-
sion, known as the canyon, is the site of receptor
attachment for the major group rhinoviruses and is
thought to be a site of receptor attachment for coxsack-
ieviruses and polioviruses [30,33–38].
In addition to binding antiviral agents, the inhibitor-
binding pocket is also the binding site of unidentified
natural ligands in some picornaviruses, including PV1M,
poliovirus type 3 Sabin (PV3S), CVB3, bovine enterovirus
(BEV), and human rhinovirus (HRV) types 1A, 14, and 16
[25,28,30,39–42]. These ligands or ‘pocket factors’ have
been modeled as fatty acids based on the hydrophobic
nature of the residues that line the pocket and the shape
of the electron density observed in crystallographic
studies. It has been suggested that the pocket factor mod-
ulates the thermal stability of the virions and plays an
important role in the assembly/disassembly of the virus
particles [28,29,41].
SCH48973 is a potent broad-spectrum inhibitor of
enterovirus replication [43] synthesized at the Schering-
Plough Research Institute [44]; SCH48973 is a member of
the SCH47802 series of capsid-binding inhibitors [45].
Molecular modeling, based on the X-ray crystallographic
structure of a previous inhibitor, SCH38057, complexed
with HRV14, contributed to the discovery of this series of
inhibitors [27,46]. In cytopathic effect (CPE) assays
against five enteroviruses, SCH48973 was shown to have
significant antiviral activity, as measured by the IC50
(inhibitory concentration required to reduce virus-
induced CPE by 50%) values which range from
0.02–0.11 m g/ml. There is no detectable cytotoxicity at
50 m g/ml. More importantly, SCH48973 was also shown to
inhibit 80% of 154 clinical isolates of human enteroviruses
with an average IC50 of 0.9 m g/ml. SCH48973 also was
effective in the murine poliovirus model of enteroviral
disease. Direct intracranial inoculation of PV2L into mice
results in paralysis and death. When SCH48973 was
administered orally, it significantly increased the survival
of the infected mice. These in vivo studies show that
SCH48973 inhibits viral replication at doses as low as
3 mg/kg/day in mice.
The three-dimensional structures of two of the three
serotypes of polioviruses have been previously deter-
mined: PV1M and PV3S [39,40]. We present here the
structure determination of an isolate of the third serotype
962 Structure 1997, Vol 5 No 7
of polioviruses: the mouse neurovirulent PV2L strain in
complex with antiviral agent SCH48973. Knowledge of
the structures of all three serotypes of poliovirus permits,
for the first time, a comprehensive comparison of the
structural differences among all known serotypes of a
human virus. Structural differences among the poliovirus
serotypes occur primarily in the loop regions of the viral
coat proteins, most notably in the loops of VP1 that cluster
near the fivefold axes of the capsid, possibly suggesting
that some of the conformational changes required for
infectivity and involved in control of capsid stability and
mouse neurovirulence may occur in the vicinity of the
fivefold axis of the poliovirion. Unlike other structures of
enteroviruses that have been described, the entire
polypeptide chain of PV2L VP4 is visible in the electron
density, and bases of the genomic RNA are observed
stacking with conserved VP4 aromatic residues.
Results and discussion
Structure determination and electron-density map quality
PV2L was purified and cocrystallized in the presence
of SCH48973 [43]. The structure of the PV2L–SCH48973
complex was determined using the molecular replace-
ment method with PV1M as the starting model [39].
The initial electron-density map was averaged using the
30-fold noncrystallographic symmetry (NCS) present
in the crystallographic asymmetric unit. The overall
quality of the averaged electron-density map was excel-
lent (Figure 1a). The electron-density map clearly
showed differences in the amino acid sequence between
the PV1M starting model and PV2L. The quality of
the averaged electron-density map allowed unam-
biguous fitting of the PV2L sequence. Electron density
was missing or very weak for the following regions: VP1
1001–1023, 1096–1101; VP2 2001–2009; and VP3
3236–3238 (the numbering system for the viral proteins is
of the form VXXX, where V is the number of the viral
protein, VP, and XXX is the amino acid number of the
VP). Residues for which the sidechain density was
missing or very weak are Lys1039, Arg2072, Lys2073,
Thr2168, Asn2169, Ser2243, Val4060, and Leu4061.
Clear, continuous electron density, corresponding to the
antiviral agent, SCH48973, was present in the hydropho-
bic pocket of VP1 (Figure 1a).
Overview of the structure of PV2L
Consistent with other RNA viruses and picornaviruses
whose structures have been determined, VP1, VP2, and
VP3 share a common core structure of an antiparallel
eight-stranded b -barrel motif. In addition, as expected
based on sequence comparisons [47], PV2L is very similar
in overall structure to PV1M and PV3S. One copy each of
VP1, VP2, VP3, and VP4 form protomers that are the
building blocks of the virion capsid. VP1 is located near
the fivefold axes of symmetry and VP2 and VP3 near the
threefold axes of symmetry (Figure 2). The pentamers are
partially held together by the N-terminal extensions of
VP1, VP2, and VP3 and by all of VP4, which form an elab-
orate network on the interior of the virus. The connecting
loops of the antiparallel eight-stranded b -barrel and the C
Research Article  Structure of PV2L complexed with SCH48973 Lentz et al. 963
Figure 1
Stereo view RAVE 30-fold averaged (2Fo–Fc)
f av electron-density maps showing the overall
quality of the maps; the model is the X-PLOR
refined model. (a) The antiviral inhibitor,
SCH48973, is shown bound in the
hydrophobic pocket of VP1. The protein is
colored cyan, and SCH48973 is colored
yellow. Some of the residues that are close to
the antiviral agent are labeled. (b) Planar
pieces of residual electron density are shown
which may correspond to RNA nucleotide
bases. The RNA bases could stack with
Tyr4020 of VP4 (cyan) and Phe4046 (yellow)
from a fivefold symmetry-related VP4
molecule. Purine (guanine) and pyrimidine
(cytosine) bases have been modeled into the
planar pieces of electron density. 
termini of VP1, VP2, and VP3 are exposed on the surface
of the virion. The well characterized N-Ag sites and the
putative site of receptor attachment, the canyon, are also
located on the surface of the virion [39,48–50].
Comparison of PV2L with PV1M and PV3S
Consistent with the high degree of sequence homology
among the three poliovirus serotypes (> 80% amino acid
identity for the capsid proteins), the antiparallel eight-
stranded b -barrel cores of PV1M and PV3S (which share
826 structurally equivalent residues) superimpose with
those of PV2L with root mean square (rms) deviations of
0.54Å and 0.50Å, respectively. Figure 3 shows the devia-
tions (in Å) of each of the Ca positions of PV1M and PV3S
when compared to PV2L. Most regions of the structures
are similar to each other, however, significant differences
among the structures occur in the exposed loop regions of
the capsid, especially in the loops of VP1 near the fivefold
vertices (Figure 4). This finding is consistent with the
fact that, of all the capsid proteins, VP1 has the lowest
sequence conservation among the three serotypes [47].
Other differences among the poliovirus serotypes occur in
regions where insertions and deletions occur in the amino
acid sequence. All of the insertions and deletions are
accommodated on the inner and outer surfaces of the
virion and result in significant, but localized, structural dif-
ferences. As can be seen from Figure 3, the most signifi-
cant structural changes among the three serotypes of
poliovirus occur at the N-Ag sites. The N-Ag sites are the
loci of greatest sequence diversity among the poliovirus
serotypes [47]. It is likely that not only the amino acid
sequences of the N-Ag sites, but also the local conforma-
tions of the segments that compose the sites, contribute to
the antigenic differences observed among the serotypes,
and also possibly to the differences observed in the host
range specificities and receptor-binding properties of the
poliovirus serotypes. 
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Figure 2
Ribbon representation of a pentamer of PV2L.
VP1 is shown in dark blue, VP2 in green, VP3
in red, VP4 in cyan, and SCH48973 is in
yellow [118]. One protomer is displaced for
clarity. The locations of the fivefold, threefold,
and twofold axes of symmetry are indicated.
The pseudo-threefold axes of symmetry are
located at the interprotomer interfaces. 
The differences observed among the structures of the three
poliovirus serotypes are consistent with the findings of
others comparing the structures of different viral serotypes
[28,40,51]. The antiparallel eight-stranded b -barrel provides
the essential structural scaffolding of the viral capsid and
would not be expected to accommodate the degree of struc-
tural changes that the loop regions can tolerate. The loop
regions are not as constrained by the b -barrel core structure
and therefore can tolerate greater structural variation. This
concept is supported by the fact that a number of viable
chimeric viruses have been generated by inserting foreign
sequences into loop regions of icosahedral RNA viruses
[15,52–57]. As the loop regions are the loci of the major
structural differences, it is likely that they are important
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Figure 4
Stereo view superposition of PV1M
(magenta), PV3S (yellow) and PV2L (cyan).
The superposition of the VP1 loop region near
the fivefold axis of the virion showing the
conformational variation of the loops among
the three serotypes of poliovirus. The VP1
BC, DE, and HI loops are labeled. The VP1
BC loop of PV2L (cyan) is not included as it is
disordered in the structure.
Figure 3
Plots of the Ca distances from PV1M and
PV3S to PV2L, based on superposition of
PV1M and PV3S onto PV2L. Plots are shown
for (a) VP1, (b) VP2, (c) VP3, and (d) VP4.
For VP1, VP2, and VP3 the b strands that
comprise the b -barrel core of each VP ( b B–b I)
are labeled above the plots. The locations of
the N-Ag sites, with (I) representing portions
of the N-AgI site, (II) representing portions of
the N-AgII site, and (III) representing portions
of the N-AgIII site, are also shown.
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determinants of both the antigenic and receptor-binding
specificities of the three serotypes of poliovirus.
Antiviral compound SCH48973
Clear electron density for the SCH48973 antiviral agent
(Figure 5a) is present in the antiparallel eight-stranded b -
barrel pocket of VP1 (Figure 1a). The asymmetric nature
of the electron density permitted the SCH48973 antiviral
compound to be uniquely oriented in the binding pocket.
The compound binds with the dichloro-substituted
phenyl ring occupying the innermost region of the pocket
and the methoxy-substituted phenyl ring occupying the
exterior portion of the pocket. The antiviral agent is sand-
wiched between residues Tyr1159, Phe1237, and
Phe1134 of VP1, making extensive van der Waals con-
tacts with these residues which results in an overall
bending of the inhibitor around Phe1134 (Figure 5b).
This bending, around the corresponding structurally
equivalent residues in group A rhinoviruses and
polioviruses, has been observed previously with other
antiviral agents and pocket factors bound to these picor-
naviruses [28,29]. Rhinoviruses have been divided into
groups A and B based on their sensitivity to capsid-
binding antiviral agents [58]. Others have noted that the
sensitivity of polioviruses to capsid-binding antiviral com-
pounds is similar to group A rhinoviruses, with both pre-
ferring to bind longer antiviral compounds [32]. Results
from crystallographic studies show that when antiviral
agents bind to polioviruses and to the group A rhi-
noviruses, the inhibitor molecule has a bent conformation
[32]. In contrast, antiviral agents bound to group B rhi-
noviruses adopt a more extended conformation [32].
Although the drug-binding pockets of group A rhi-
noviruses and polioviruses share some common features,
they also have significant differences: pocket factors are
not usually found bound to group A rhinoviruses, and
SCH48973, although a potent inhibitor of polioviruses, is
a poor inhibitor of HRV14, a group A rhinovirus.
Whether or not there is a natural pocket factor associated
with PV2L cannot be determined from the current struc-
ture as its binding pocket is occupied by SCH48973.
SCH48973 is a very potent inhibitor of PV2L with a Ki of
8.9 · 10–8 M [43]. It is well documented that binding of
antiviral agents to picornaviruses can displace the natural
pocket factors [28–30]. Except for the outer portion of the
pocket, all the residues that line the pocket are
hydrophobic and as a result all of the short protein con-
tacts with the antiviral agent are hydrophobic in nature
(Figure 6). The antiviral agents have been suggested to
enter the pocket via two possible mechanisms: entrance
through a narrow ‘pore’ connecting the outer region of
the pocket to the canyon floor; or entrance through a ‘trap
door’ movement of b sheets of VP1 [29]. Either mecha-
nism requires flexibility of the antiviral agent and/or the
viral capsid. Located in the vicinity of the pore at the
outer portion of the pocket are two tyrosine residues
(1112, 1205) and one histidine (1207) that may contribute
to the flexibility of the antiviral binding pocket. It has
been suggested that the sidechains of tyrosines con-
tribute to the flexibility of antibody binding sites due to
their ability to participate in both hydrophobic and
hydrophilic interactions [59]. Analogies have been noted
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Figure 5
The chemical structure of SCH48973 and the superposition of
SCH48973 (gray; bound to PV2L) and the sphingosine pocket factor
(black; bound to PV1M). (a) The chemical structure of SCH48973. (b)
The superposition of SCH48973 and sphingosine, based on 830
structurally equivalent protein atoms from PV2L and PV1M,
respectively. The figure shows the distinct bend in SCH48973 and the
pocket factor; the labels exterior and interior relate to the virus
hydrophobic pocket. SCH48973 and sphingosine bind in a very similar
mode, only diverging near the entrance to the pocket.
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previously for multifaceted roles of tyrosines in the picor-
navirus antiviral binding site [31] and in the nonnucleo-
side inhibitor binding site of human immunodeficiency
virus type 1 (HIV-1) reverse transcriptase [60].
Superposition of the VP1 pocket regions of all three
poliovirus structures reveals that SCH48973 binds in a
manner very similar to that of the natural pocket factors of
PV1M and PV3S (Figure 5b). SCH48973 spans 17Å of the
PV2L pocket length. The amount of solvent-accessible
surface area buried in the complex is 990Å2, which is
within the range of most stable protein–protein interac-
tions (600–1000Å2) [26,61,62]. Almost all of the solvent-
accessible surface area of the SCH48973 inhibitor is
buried in the complex (>98% of the total 640Å2). The
positions of the pocket residues and the surrounding
structure change very little when comparing PV1M and
PV3S to PV2L bound with SCH48973. Furthermore, com-
parisons of the structures of PV1M and PV3S bound to
natural pocket factors and to diverse capsid-binding antivi-
ral agents also show few structural changes outside the
pocket region [29]. By analogy, we would expect that the
native structure of PV2L is very similar in structure to the
PV2L–SCH48973 structure presented here, assuming that
the native PV2L binds a pocket factor in the absence of
antiviral agent, as has been observed for PV1M and PV3S.
Thus, it is not surprising that PV2L receptor attachment is
not inhibited by SCH48973 [43]. SCH48973 does not
block the attachment of PV2L to HeLa cells, but, like
other picornavirus capsid-binding inhibitors, stabilizes the
virus to heat inactivation and blocks viral uncoating [43].
This is in contrast to the large (up to 4.5Å) conformational
changes seen in HRV14 upon binding antiviral agents
where receptor attachment is inhibited [23,27].
The broad-spectrum inhibitory activity of SCH48973
against many different enteroviruses may be due to the
hydrophobic interactions of SCH48973 with the viral
capsid. There are no hydrogen bonds between SCH48973
and the pocket residues of PV2L. Lack of polar binding
determinants in a predominantly hydrophobic pocket may
permit greater latitude in the binding of SCH48973 to a
broad range of enteroviruses.
The ion at the fivefold axis
Located on the fivefold axis, at a radius of 125Å from the
center of the virus, is a strong electron-density feature that
appears be an ion bound by Asn3006 that ‘plugs’ the five-
fold axis. This electron-density feature is similar to a
feature described in BEV where Thr3004 binds what the
authors suggest is an ion molecule [41]. In PV2L the puta-
tive ion is coordinated by oxygens from fivefold symme-
try-related asparagine residues with ion–ligand distances
of 3.5Å. A single water molecule is located directly above
the ion at a distance of 2.9Å. Calcium and zinc have been
associated with the life cycles of several icosahedral
viruses [63–68]. Consideration of the stereochemical
arrangement of coordinating ligands suggests that the ion
could be Ca2+. Ca2+ ions are usually coordinated by six,
seven, or eight ligands (typically oxygens) with ion–ligand
distances ranging from 2.0–3.2Å, the average distance
being 2.4Å [69]. Although the distances from the PV2L
asparagines to the putative ion are relatively long, Ca2+
ion–ligand distances of 3.7Å have been reported for a
putative Ca2+ ion located on the fivefold axis of HRV1A
[70]. Ca2+ was not included in the crystallization medium,
however, it is possible that the ion was carried throughout
the purification scheme. The assignment of this ion as a
Ca2+ appears to be preferable to alternatives such as Li+
(from the crystallization medium), Na+, K+, Mg2+, or Zn2+,
yet given the relatively unusual coordination geometry,
must be regarded with caution.
VP4 and the myristic acid moiety
The VP4 N termini of polioviruses, as well as other
picornaviruses, have been shown to be myristylated
[30,40,41,71]. Consistent with this finding is the observa-
tion that worm-like electron density extends from the N-
terminal glycine of VP4 in PV2L. This electron density
has been modeled as myristic acid (a C14 fatty acid) in
PV2L. The electron density is continuous from C1 to C10
of the myristate and is essentially identical in position to
the corresponding moiety in PV1M [39]. No electron
density is present for C11–C14 of the myristate. As seen in
the other poliovirus structures, the carboxylate oxygen of
the myristic acid moiety is hydrogen bonded to the
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Figure 6
The antiviral agent in the pocket of VP1 and its location relative to the
canyon region [118]. VP1 and VP3 are shown in blue and red ribbon
representation, respectively. SCH48973 is colored according to atom
type: carbon atoms green; oxygen atoms red; and chlorine atoms cyan.
Sidechains near the inhibitor are shown in yellow. All the protein
contacts to SCH48973 are hydrophobic in nature. 
sidechain oxygen of Thr4028 from an adjacent fivefold-
related protomer. This interaction has been seen in a
number of picornavirus structures and mutagenesis
studies have suggested that Thr4028 plays an important
role in poliovirus assembly and infectivity [72].
The myristic acid groups cluster on the interior of the
virion near the base of the fivefold axes. Located directly
above the myristic acid groups is the b -annulus structure
formed by the N-terminal extensions of VP3, including
Asn3006 which coordinates the putative ion molecule.
Directly below the myristic acid groups, weak, but some-
what connected electron density is present that may belong
to the N-terminal residues of VP1 that are not currently
included in the model (1001–1023). These are the only
amino acid residues missing from the model that could be
in this vicinity. This finding is entirely consistent with
weak electron density in this region that has been assigned
as part of VP1 in the structures of PV1M and PV3S [39,40].
In the models of PV1M and PV3S, several amino acids of
the N terminus of VP1 have been modeled into weak elec-
tron density so that the N-terminal VP1 residues form a
portion of a b -sheet structure with the N terminus of VP4.
Placement of the N terminus of VP1 near the fivefold axes
of the virion and in close contact with VP4 is consistent
with one proposed mechanism of A particle formation [40].
In the formation of A particles, loss of VP4 and externaliza-
tion of the N terminus of VP1 may be coupled. 
Unlike the structures of PV1M and PV3S, the model of
PV2L contains all the amino acid residues of VP4
(4002–4069; 4001 is the myristic acid moiety). Residues
4017–4022 of VP4 are missing in the PV1M and PV3S
models [39,40]; for PV2L, clear continuous electron
density is present for these amino acid residues. In fact,
this region is disordered in all enterovirus structures deter-
mined to date, except PV2L. This portion of VP4 of PV2L
forms two small helical segments that are connected by a
short loop region (Figure 2). This segment of VP4 has
close interactions with VP4 from a fivefold symmetry-
related protomer, contributing to the interior network of
interactions that stabilize pentamers.
Potential RNA interactions with aromatic residues in VP2
and VP4
Several residual electron-density features in the averaged
electron-density maps have been tentatively assigned to
nucleotide bases of the genomic RNA. A flattened, planar
piece of electron density is located approximately 4.0 Å
from, and parallel, to the indole ring of Trp2038. A similar
fragment of electron density has been seen in the
structures of several picornaviruses including rhino-
viruses, polioviruses, and coxsackieviruses [30,32,40,73,
74]. Trp2038 is a highly conserved amino acid residue in
the picornavirus family. Recently it was shown through
mutagenesis studies that Trp2038 is required for virus
viability in HRV16 and that, of the four mutations made,
only a phenylalanine substitution at this position resulted
in viable virus [74]. This interaction of Trp2038 of the
viral protein with the RNA occurs near the twofold axes of
the virion in the vicinity of a seven-stranded cross-pen-
tamer b sheet thought to be important for virus stabiliza-
tion [40]. Mutation of Ser2031fi Thr in this region confers
the mouse-adapted phenotype to PV1M [13]. Trp2038 is
located on the edge of a trefoil-like depression found in
the PV1M empty capsid structure, that has been sug-
gested to bind RNA during capsid assembly. This obser-
vation has led to the suggestion that the binding of RNA
helps to catalyze the assembly of pentamers and the cleav-
age of VP0 into VP4 and VP2 [5]. Indeed, poliovirus 14S
pentamers have been shown to interact with RNA [75].
A previously undescribed RNA base pair appears to inter-
act with residues of VP4 near the fivefold axes. The flat-
tened pieces of electron density are in positions consistent
with RNA nucleotide bases interacting with the aromatic
rings of Tyr4020 and Phe4046 from a fivefold symmetry-
related VP4 chain (Figure 1b). A purine and a pyrimidine
RNA base have been modeled into the electron density.
Tyr4020 is located on a portion of VP4 which is disordered
in all other enterovirus structures which have been deter-
mined. Among polioviruses, rhinoviruses and coxsack-
ieviruses, the residues corresponding to Phe4046 of PV2L
are invariably large hydrophobic amino acids phenylala-
nine, tyrosine or leucine) and are usually aromatic.
Tyr4020 is conserved among polioviruses. It is possible
that the interaction of the putative RNA base with
Tyr4020 helps to organise this section of VP4 or vice versa.
In this region there is a cluster of arginine residues,
including the highly conserved Arg1129. When Arg1129 is
mutated in polioviruses, virus assembly and RNA encapsi-
dation are impaired [76]. Also in this vicinity is residue
Ala1024, the first ordered amino acid of VP1 in PV2L.
While it may be possible that the unaccounted for electron
density corresponds to the missing N-terminal amino acids
of VP1, there are no aromatic residues in the missing
sequence [47]. The interaction of VP4 with RNA, and
with the VP1 N terminus near the fivefold axes, suggests a
possible mechanism by which loss of VP4 and external-
ization of the VP1 N terminus can lead to RNA release,
possibly via the fivefold axes of the virus particle. 
Structural differences near the fivefold axes
The most significant structural differences among the
three serotypes of poliovirus occur in VP1 and cluster
toward the outer surface of the virion near the fivefold
axes of symmetry. Large structural differences (up to
4.5Å) are observed in the DE and HI loops of VP1
(Figures 3 and 4). Unlike the VP1 BC loops of PV1M and
PV3S, the BC loop of PV2L (residues 1096–1101) is struc-
turally disordered. The VP1 BC loop of PV2L potentially
could have been cleaved with proteases, such as trypsin,
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during the propagation and purification protocols, which
could account for the disorder in this region [77].
However, SDS-PAGE analysis of the virus samples used
for crystallization of PV2L show that the VP1 polypeptide
is intact (data not shown). The BC loop of poliovirus VP1
forms part of the N-AgI site and has been shown to be a
determinant of the mouse neurovirulent phenotype in the
case of PV2L [11]. When amino acids 1094–1102 of the
PV1M strain are replaced with the corresponding residues
from the PV2L strain, the resulting chimera, V510, is neu-
rovirulent in mice [15,78]. The three-dimensional struc-
ture of the V510 chimera has been determined and shows
that the VP1 BC loop of PV1M containing the PV2L
replacement is well ordered in the electron density [79].
The structure of the BC loop of the chimeric virus,
however, is significantly different from the structures of
the VP1 BC loops of both PV1M and PV3S [79]. The
structure of PV2L could not be compared in detail to the
V510 chimera because the coordinates for this structure
have not been made available. The electron density
present for amino acids 1093–1095 and 1102–1105 of
PV2L seems to indicate that the VP1 BC loop of PV2L is
similar in structure to PV3S and V510 at the C-terminal
region of the loop, but different from both PV1M and
PV3S at the N-terminal region. The sequence at the C
terminus of the VP1 BC loop (Lys/Arg-Leu-Phe for amino
acids 1103–1105) is conserved among the three poliovirus
serotypes, but the three-dimensional structure of this
segment varies significantly among the different
serotypes. It is interesting to note that the structure of a
complex between a peptide, corresponding to the viral
epitope (1086–1104 of PV1M), and a Fab fragment of C3,
a neutralizing antibody for polioviruses, shows that por-
tions of the peptide (1100–1003) adopt a dramatically dif-
ferent conformation from the corresponding segment of
the native PV1M virus [80]. When a docked Fab–PV1M
virus model is made from the C3–peptide complex, the
model is inconsistent with biochemical and neutralization
data, suggesting that some conformational changes in the
VP1 BC loop must occur upon antibody binding [80]. Fur-
thermore, this sequence was found to be highly flexible
by NMR studies when inserted into several sites of
maltose-binding protein [81]. At low contour levels, some
residual electron density is present for amino acids
1096–1101 in PV2L indicating that this portion of the BC
loop is located further from the fivefold axis of the virion
than are the BC loops of PV1M and PV3S. This would
suggest that the VP1 BC loop of PV2L is more surface
exposed than those of PV1M and PV3S. This obser-
vation is consistent with the fact that the N-AgI site is
immunodominant in PV2L [48,82]. 
Mouse adaptation and the VP1 BC loop
How does the BC loop of VP1 control mouse adaptation?
All three polioviruses utilize the same receptor in pri-
mates [83], however, only PV2L is able to replicate in the
mouse central nervous system. Because all poliovirus
serotypes can replicate in murine cells when transfected
with poliovirus RNA [84], the mouse adaptation of
poliovirus must primarily occur in one of the early events
of infection, such as receptor attachment, cell entry,
and/or viral uncoating. Recently, however, it was shown
that the host range of polioviruses could also be altered by
muta-tions in the 5 ¢ nontranslated region of the genomic
RNA, specifically at the internal ribosomal entry site
(IRES), suggesting that cellular host factor(s) involved in
IRES-dependent translation differ between human and
murine cells and may play a role in determining host
range specificity [85]. A murine homolog of the PVR has
been identified, however, it does not serve as a receptor
for the polioviruses [86]. The actual murine PVR has not
been identified. The VP1 BC loop of polioviruses is
located in the vicinity of the canyon region, the proposed
binding site of the PVR, and could be involved in directly
contacting the murine PVR. The VP1 BC loop of PV2L
seems to be more flexible (i.e. it is structurally disordered)
than the corresponding loops in the other poliovirus
serotypes and, therefore, may make more favorable con-
tacts with the murine receptor than the corresponding
loops in PV1M and PV3S. Sequence and conformational
differences in the VP1 BC loop region among the
poliovirus serotypes could account for the differences in
mouse adaptation. 
Having a portion of the receptor-binding site overlapping
with an antigenic site is not suggested by a strict interpre-
tation of the canyon hypothesis, which predicts that
residues important for receptor binding should be inacces-
sible to the host’s immune system [34]. Recent structural
studies of HRV14 bound with a neutralizing antibody
have shown that the neutralizing antibody not only con-
tacts the epitope on the Nlm-IA site, but also contacts
some regions of the canyon [42]. A portion of the contacts
overlap with the footprint that HRV14 makes with its
receptor, intercellular adhesion molecule 1 (ICAM-1),
however, the monoclonal antibody does not seem to
contact residues that are located in the deepest regions of
the canyon [42]. Others have shown that the antigenic
sites and receptor-binding sites of polioviruses do overlap
to some extent, a finding that could explain why there are
only three poliovirus serotypes [6]. Recent studies demon-
strate significant serotype-specific differences in the inter-
actions of polioviruses with mutant PVRs [87]; some of
these differences were mapped to residues that are
responsible for determining poliovirus antigenicity.
Another picornavirus, foot-and-mouth disease virus
(FMDV), has its receptor-binding site on a mobile (disor-
dered) surface loop (GH loop of VP1) close to an antigenic
site [88]. In another RNA virus, HIV-1, the V3 loop of the
gp120 glycoprotein has been shown to be an impor-
tant immunogenic site, as well as a key determinant of
cell tropism [89,90]. Indeed, it has been suggested that
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antigenic variation of RNA viruses is not entirely depen-
dent on immune selection [91]. 
If the VP1 BC loop of PV2L does directly contact the
murine PVR, then the nature of the interaction of PV2L
with the murine PVR must be different from the inter-
action with the human PVR. In particular, the VP1 BC
loop of polioviruses, including PV2L, is not necessary for
poliovirus infection of cultured primate cells, as the VP1
BC loop of polioviruses can be cleaved with trypsin or
removed entirely without loss of infectivity [92,93].
Many examples of the generation of viable chimeric
viruses by the insertion of heterologous amino acid
sequences into the VP1 BC loop of polioviruses have also
been reported [15,52,53,55,94,95]. Cleavage of the BC
loop of PV2L with trypsin does, however, result in a sig-
nificant reduction (1000-fold) of its virulence in mice
[12]. Attenuating mutations that reduce murine neurovir-
ulence and lead to a temperature-sensitive (ts) pheno-
type of PV2L have also been mapped to the BC loop of
VP1 [96]. These results support the importance of the
VP1 BC loop of PV2L in determining host range. Knowl-
edge of the precise nature of the interactions of
poliovirus with the human PVR and the murine PVR
awaits identification of the murine PVR and structure
determination of the complexes.
A connection between mouse adaptation of poliovirus and
the potential involvement of the VP1 BC loop in the con-
formational changes required for infectivity has been pro-
posed [79]. It has been reported that the PVR induces
structural changes in polioviruses that include the forma-
tion of A particles in which VP4 has been lost and the N-
terminus of VP1 becomes surface exposed [17]. The
murine PVR may be able to bind to all three serotypes of
poliovirus, but may not be capable of inducing the struc-
tural changes in PV1M and PV3S required for infectivity.
The residues forming the loop regions around the fivefold
axes of the particle (including the VP1 BC loop) may play
important roles in modulating the receptor-induced con-
formational changes by making the changes more energet-
ically favorable. In fact, not only do the conformations of
the VP1 BC loop differ among serotypes, but the confor-
mations of the DE and HI loops of VP1 also vary
(Figure 4). The DE and HI loops have greater amino acid
sequence conservation among the three serotypes than do
the BC loops (Figure 7) [47], but significant structural
changes are present in these regions of VP1. As suggested
previously [40,79], it is possible that the VP1 BC loop con-
formation has a dramatic effect on the structure of this
entire region, affecting the structure of the DE and HI
loops and possibly affecting the flexibility of the capsid.
The structure of PV2L supports this idea. Although the
amino acid sequences of the VP1 DE and HI loops are
very well conserved among the three poliovirus serotypes
(Figure 7), the structures of the loops show substantial dif-
ferences (Figure 4). Interesting analogies between the dif-
ferent serotypes of FMDV and poliovirus exist in this
regard. In the case of FMDV, it has been suggested that
the flexibility of the antigenic/receptor-binding loop (GH
loop of VP1) not only directly affects antigenicity, but also
influences the conformations of other nearby sites thereby
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Figure 7
Amino acid sequence comparison of the VP1
BC, DE, and HI loops near the fivefold axes. Loop Loop sequences
BC 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105
PV1M Val Asp Asn Pro Ala Ser Thr Thr Asn Lys Asp Lys Leu Phe
PV2L • • • Asp Ala Pro • Lys Arg Ala Ser • • •
PV3S • • • Glu Gln Pro • Thr Arg Ala Gln • • •
DE 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153
PV1M Phe Thr Glu Thr Asn Asn Gly His Ala Leu Asn Gln
PV2L Tyr • Asp Ala • • • • • • • •
PV3S Phe • Asn Ala • • • • • • • •
HI 1245 1246 1247 1248 1249 1250 1251 1252
PV1M Val Asn Asp His Asn Pro Thr Lys
PV2L • • • • • • • •
PV3S • • • • • • • •
facilitating structural ‘cross-talk’ between these regions
[51,97]. In one case, changes in the antigenicity of FMDV
were coupled to changes in host-cell interactions [97].
Surface differences among the poliovirus serotypes:
implications for mouse adaptation and temperature
sensitivity
When the solvent-accessible surface areas of the three
serotypes are compared with each other, it is clear that
PV2L has a more prominent surface depression located at
the fivefold axes of symmetry (Figure 8a). This is the
result of an overall movement of the DE and HI loops of
VP1 away from the fivefold axis. The VP1 DE loop of
CVB3 has been suggested to play a role in stabilizing
the intrapentamer interface by interacting with fivefold
symmetry-related protomers [30]. In PV2L, His1149 is
completely moved away from the fivefold axis relative to
its position in the structures of PV1M and PV3S
(Figure 8b); the imidazole ring of His1149 in the VP1 DE
loop interacts with residues from a fivefold symmetry-
related DE loop forming possible hydrogen bonds to the
carbonyl oxygen atoms of 1144 and 1147 and stacking with
the aromatic ring of Tyr1142. The more open conforma-
tion of the VP1 BC, DE, and HI loops in this region of
PV2L may make conformational changes more energeti-
cally favorable. It is quite striking to observe a prominent
surface depression in the mouse-adapted PV1M chimera,
V510, at the fivefold axis, very similar to the depres-
sion found in PV2L (shown in Figure 6 in Yeates et al.)
[79]. The surface depression in the V510 chimera,
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Figure 8
Elements of the fivefold axes of the three
serotypes of poliovirus that could be involved
in determining host-range specificity and
conformational stability. GRASP surface
representations of pentamers of (a) PV1M,
(b) PV3S, and (c) PV2L calculated using a
spherical solvent probe with a 1.4 Å radius
[119]. In the case of PV1M and PV3S, amino
acids 96–102 (the VP1 BC loop) were
removed prior to the surface calculation, as
these residues are missing from the PV2L
model. There is a large surface depression at
the fivefold axis of PV2L when compared to
PV1M and PV3S. Ribbon representations of
the fivefold axes of (d) PV1M, (e) PV3S, and
(f) PV2L. The fivefold symmetry-related
protomers are shown in different colors for
clarity. In PV1M and PV3S, residues from the
VP1 DE loop totally (PV1M) and partially
(PV3S) occlude the fivefold axis. In PV2L, the
fivefold axis is significantly more open than
compared to PV1M and PV3S. This is
accomplished, in part, by movement of
residues Asn1146, Asn1147, and His1149 of
PV2L away from the fivefold axis.
however, is more shallow than the corresponding one
in PV2L, as His1149 of V510 still appears to occlude the
fivefold axis [79].
The importance of the loops that cluster near the fivefold
axes of PV2L is further supported by the observation that
a possible determinant of attenuation of poliovirus type 2
Sabin (PV2S) is located in this region. In one study, a sub-
stitution of Thr1143fi Ile, located on the DE loop of VP1
near the fivefold axis (Figure 8b), was found to be a
general determinant of attenuation of PV2S [98]. A more
recent study contradicted the previous results [98], but did
find that an isoleucine residue at position 1143 in PV2L
was highly unstable both in vitro and in vivo mutating to
several different amino acids [99]. Replacing Thr1143
with an isoleucine residue would place a more hydropho-
bic residue in a surface-exposed region of the virion,
potentially affecting the conformation and/or stability of
the VP1 DE loop and the surrounding loops in this region,
including the VP1 BC and HI loops. A comparable situa-
tion exists for the PV3S strain where a Ser3091 fi Phe
substitution, located in the BC loop of VP3 near the
pseudo-threefold axes of symmetry, identified this residue
as an important determinant of attenuation and of temper-
ature sensitivity for this virus. It has been suggested that
replacement of the serine with the more hydrophobic
phenylalanine at this position could destabilize the virus
particle leading to temperature sensitivity. This amino
acid has also been implicated in playing a role in the con-
formational transitions required for infectivity [40].
The structural differences between the mouse neuroviru-
lent strains of poliovirus (PV2L and V510) and those that
are mouse restricted (PV1M and PV3S) may give some
important clues to the mysterious structural changes that
occur upon receptor binding. All significant struc-
tural changes between the mouse-adapted and mouse-
restricted strains occur in the vicinity of the fivefold axes
[79; this study]. VP4, which is lost during the formation of
the A particle, is located directly below each fivefold axis.
Also directly below the fivefold axis is the N terminus of
VP1, which has been shown to be surface exposed in the A
particle and is also involved in the binding of the A parti-
cle to liposomes [18]. The N terminus of VP1 has been
proposed to form an amphipathic a helix that could insert
into membranes [100]. Indeed, the VP1 N terminus of
HRV16 has been shown to fold as an amphipathic a helix
that is in close association with VP4 located at the base of
the fivefold axis of symmetry [74]. By analogy with the
DNA virus fX174, which is known to extrude its DNA
through the fivefold axis [65], poliovirus could also use its
fivefold axis as a channel through which VP4 is lost, VP1 is
extruded, and/or RNA is ejected. In fact, the fivefold axes
of picornaviruses have been suggested to have properties
similar to ion channel like proteins [30,101]. A recent
report has shown that polioviruses, both in the native form
and in the A form, can produce ion channels in planar lipid
membranes, possibly utilizing a mechanism that involves
the N terminus of VP1 and the myristylated VP4 [102]. 
Model for picornavirus disassembly and initiation of
infection
Several other mouse adaptation determinants have been
identified in the capsid region of PV1M that do not
directly involve the BC loop of VP1 [12–14]. The locations
of many mutations that correlate with the mouse-adapted
phenotype, at the interfaces of protomers, as well as in
VP4 and the N terminus of VP1, have led to a proposal for
the disassembly of picornaviruses. In this model, disas-
sembly would occur via separation of the protomers within
a pentamer at the pseudo-threefold axes [40]. This situa-
tion might be analogous to the conformational changes
that occur in tomato bushy stunt virus when the pH is
increased and calcium is removed [63]. The additional
poliovirus mouse adaptation mutations are thought to
destabilize the virion, perhaps at the pseudo-threefold
protomer interface, thereby making the structural transi-
tions required for infectivity more favorable [40]. It still
remains unclear, however, as to exactly how some of these
mutations may destabilize the virion. Many of these
mouse adaptation mutations occur at positions that could
interact with VP4. A recent study has shown that several
PV1M mouse-adapted viruses were converted more effi-
ciently to A particles when compared to native PV1M
virions, suggesting that host restriction in the
mouse central nervous system might be overcome by
facilitation of receptor-mediated conformational changes
[103]. In one of the PV1M mouse-adapted mutants
(VP1 Thr1022fi Ile), viral RNA release was facilitated.
Many of the mouse-adapted mutant viruses were also
found to be temperature sensitive and to have defects in
virion assembly. 
Any uncoating mechanism involving the separation of pro-
tomers within pentamers, whether at the fivefold axes or
at the pseudo-threefold axes, requires flexibility of the
viral capsid. The binding of natural pocket factors and
antiviral agents has been suggested to modulate the flexi-
bility of the viral capsid [28,29]. It was recently reported
that upon binding of antiviral agents to HRV16, there was
a reduction in the flexibility of both the VP1 b barrel and
the N terminus of VP3 [74]. The N terminus of VP3 is
located near the fivefold axes of the virion and extends to
the pseudo-threefold axes. Potentially there is some cross-
talk between the binding pocket of VP1 and the N termi-
nus of VP3. It is interesting to note that the only other
close contacts between the antiviral agents and the viral
capsid, besides contacts with VP1, occur with residues in
the N terminus of VP3. In fact, Ala3024, which is com-
monly found in contact with antiviral agents, is highly
conserved among picornaviruses [47]. In rhinoviruses,
residues at the N termini of VP3 and VP1, and the
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Ca2+-ion binding site become more disordered upon low-
ering the pH, a condition that leads to destabilization of
the virion [104]. Uncoating mechanisms that postulate
conformational changes occurring near the fivefold axes or
near the pseudo-threefold axes need not be mutually
exclusive. It is possible that conformational changes that
occur at one site may be coupled to changes at another. 
We propose a model (that shares broad similarities with
existing models [1,40,74]) that suggests dual involvement
of the particle fivefold and pseudo-threefold axes in initi-
ating infection. During initial stages of viral infection, VP4
is lost from the poliovirion, followed by exposure of the N
terminus of VP1 on the virion surface. The myristylated
VP4 is conveniently positioned to exit through the
channel along the fivefold axis, while the N terminus of
VP1 is well positioned to be exposed through the pseudo-
threefold axis. Since the N terminus of VP3 forms the b
cylinder that blocks exit of VP4 through the fivefold axis,
it is conceivable that the entire exit process of VP4 could
be initiated by collapse of the VP1 binding pocket, poten-
tially leading to breakdown of the VP3 b cylinder. Because
VP4 and the N terminus pf VP1 are in close association
with each other near the fivefold axes, loss of VP4 could
trigger exposure of the N terminus of VP1. Although a
fraction of the VP1 N termini may be externalized through
the fivefold axis, we favor the pseudo-threefold axis as a
portal for extrusion of the VP1 N termini, which would
avoid potential clogging of the pore at the fivefold axis.
Association of VP4 with the viral RNA could enhance exit
of the viral RNA, through an ion channel-like pore formed
by the fivefold axis, the myristylated VP4 molecules,
and/or the amphipathic helices possibly formed by the N
termini of VP1 [74,100]. It is possible that ejection of
virion RNA through a particular particle fivefold axis
would be successful only if the VPg-linked 5¢ terminus is
nearby, helping to explain why only a small percentage of
picornavirus particles are infectious [1]. Particles that asso-
ciate with a cell membrane via a certain fivefold axis may
become ‘committed’ to that fivefold axis, resulting in
many virion interactions with cells that are not productive
in initiating infection.
Biological implications
Polioviruses are human enteroviruses belonging to the
picornavirus family and are the causative agents of
poliomyelitis, a disease characterized by weakness or
paralysis of the extremities. The poliovirus capsid is
composed of 60 copies of  each of four viral polypeptides
designated VP1, VP2, VP3, and VP4, that are arranged
in an icosahedrally symmetric manner. The protein shell
is approximately 300Å in diameter and encapsidates a
7.5kb single-stranded genomic RNA. Unlike other
members of the picornavirus family, such as the human
rhinoviruses (>100 serotypes), polioviruses exist in only
three distinct serotypes. All three poliovirus serotypes
are neurovirulent in primates, but only one (type 2) is
neurovirulent in mice when injected intracerebrally.
Although much progress has been made in the fight
against poliomyelitis in the United States and the rest of
the Western world, largely due to the success of poliovirus
vaccines, some developing countries still have a signifi-
cant incidence of this disease. Other enteroviruses,
including the coxsackieviruses, also cause a wide range
of human diseases including respiratory illnesses, aseptic
meningitis, acute hemorrhagic conjunctivitis, and
myocarditis. Numerous antiviral agents have been syn-
thesized that are active against enteroviruses, including
polioviruses, although currently there is no approved
antiviral treatment for enteroviral infections. The results
of in vitro and in vivo studies with the antiviral agent
SCH48973 suggest that it is a promising candidate for
the treatment of human enteroviral diseases [42]. 
The structure of mouse neurovirulent poliovirus type 2
Lansing (PV2L) complexed with SCH48973 is reported
here. SCH48973 binds in the hydrophobic pocket of
VP1, in almost the same manner that natural ‘pocket
factors’ bind to other polioviruses. All close contacts of
SCH48973 with the capsid proteins are hydrophobic in
nature. Located near the fivefold axes of symmetry, the
BC loop of VP1 has been implicated as a host range
determinant of polioviruses [11,15]. The VP1 BC loop is
disordered in the PV2L structure, suggesting that it has
a high degree of flexibility. When comparing the struc-
tures of the three serotypes of poliovirus, the largest dif-
ferences are observed near the fivefold axes in the BC,
DE, and HI loops of VP1. Together these loops may
play a role in virion binding to various poliovirus recep-
tors and/or modulating the conformational changes
required for infectivity. 
For the first time in an enterovirus crystal structure, the
entire polypeptide chain of VP4 could be accounted for
by the electron density. The N terminus of VP4 was
also found to be myristylated, consistent with the other
known structures of polioviruses. Residual electron
density, tentatively assigned to an RNA nucleotide base,
was identified interacting with a conserved tryptophan
residue of VP2 located in the vicinity of the interpen-
tamer interface. This interaction has been described pre-
viously in several picornavirus structures. In addition,
electron density corresponding to a putative RNA
nucleotide base pair, that has not been observed in other
picornavirus structures, was also identified. The puta-
tive RNA interacts with a tyrosine residue from VP4
and a phenylalanine residue from a fivefold symmetry-
related VP4 chain. A model is proposed that suggests
dual involvement of the virion fivefold and pseudo-three-
fold axes in receptor-mediated initiation of infection
by picornaviruses.
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To summarise, the determination of the structure of
PV2L complexed with SCH48973 has provided insights
into the molecular determinants of antiviral agent binding,
host range specificity, and capsid stability of polioviruses.
Materials and methods
Virus propagation, purification and crystallization
Ten 175 cm2 flasks confluent with HeLa (CCL 2) cells in Eagle’s mod-
ified minimal essential medium (EMEM) with 10% fetal bovine serum
(FBS) were infected with PV2L at a multiplicity of infection (MOI) of 1.
The virus was allowed to adsorb to the cells for 45 min at 33° C. The
flasks were then overlaid with 10 ml of EMEM with 2% FBS and incu-
bated for 18 h at 37 ° C. After incubation, the supernatant was
removed and the cells were harvested by centrifugation at
20,000 rpm for 15 min in a Sorvall SS-34 rotor. The flasks were
scraped and washed using EMEM with 1% FBS. The cells were
resuspended at twice the packed cell volume (PCV) and frozen at
–70 ° C until further use.
The harvested HeLa cells were freeze-thawed three times to release
the virus and the cellular debris was removed by centrifugation at
10,000 rpm for 10 min at 4 ° C in a Sorvall SS-34 rotor. The pellet was
washed using EMEM with 1% FBS at twice the PCV and the cellular
debris was once again removed by centrifugation at 10,000 rpm for
10 min at 4 ° C in a Sorvall SS-34 rotor. The supernatants were pooled
and SCH48973 was added at 10 X the IC50 (0.4 m g/ml) and allowed
to incubate on ice for 1 h. The supernatant was then treated with
DNase I (0.1 m g/ml) and MgCl2 (to 5 mM) and allowed to incubate for
30 min at room temperature. EDTA, pH 9.5, was added to 10 mM. N-
lauryl sarcosine was added 10 min later to 0.1% at neutral pH. The
solution was clarified by centrifugation at 12,000 rpm for 10 min at
10 ° C in a Sorvall SS-34 rotor. The virus was pelleted by centrifugation
at 48,000 rpm for 2 h at 10 ° C through a 30% sucrose cushion in a
Beckman 50.2Ti rotor. The resulting virus pellet was resuspended in
10 mM Tris-HCl, pH 7.2 and loaded onto a sucrose gradient
(7.5–45%) and centrifuged at 35,800 rpm for 90 min at 10 ° C using a
Beckman SW40Ti swinging bucket rotor. The gradient was fraction-
ated and the virus bands were pooled. The virus, diluted with 10 mM
Tris-HCl, pH 7.2, was pelleted by centrifugation at 45,000 rpm for 2 h
at 10 ° C in a Beckman 50.2Ti rotor. The virus pellet was resuspended
in 0.5 ml of 10 mM Tris-HCl, pH 7.2 and the virus concentration was
determined by measuring the absorbance at 260, 280, and 310nm.
The resuspended virus was diluted with 10 mM Tris-HCl, pH 7.2 and
pelleted for a final time by centrifugation at 45,000 rpm for 2 h in a
Beckman 50.2Ti rotor. The virus was resuspended in 10 mM Tris-HCl
pH 7.2 and 0.2 M NaCl to a final concentration of 5 mg/ml. Purity of
the virus sample was assessed by silver-stained and Coomassie-
stained SDS-PAGE analysis. The entire P1 capsid coding region of
the genome was sequenced to determine the precise amino acid
sequence of the virus crystallized. No amino acid changes from the
prototypical PV2L sequence were found [105].
Crystals were grown at room temperature using a modified version of
the hanging-drop vapor diffusion method. The reservoir solution
(0.5 ml total volume) contained varying amounts of PEG 8000
(0.9–1.4%) and Li2SO4 (100–250 mM). The virus sample, 2-3 m l of a
5 mg/ml solution, was placed on a plastic coverslip and mixed with an
equal volume of the reservoir solution. The well was sealed with the
coverslip using vacuum grease except for a small leak that was left
between the coverslip and the well. After 2–4 days, crystals approxi-
mately 0.1 mm · 0.2 mm · 0.1 mm began to appear, at which time the
leak was sealed with vacuum grease and the crystals were allowed to
grow to their maximum size of 0.2 mm · 0.35 mm · 0.2 mm. Without
the leak, the crystallization drops would either form precipitate or
remain clear for months. The leak left between the coverslip and
the well was a key factor in the production of crystals suitable for X-ray
diffraction analysis.
Data collection and processing
All diffraction data were collected on crystals mounted in quartz capil-
laries at the Cornell High Energy Synchrotron Source (CHESS) using
the highly intense F1 beamline with a wavelength of 0.908 Å. X-ray dif-
fraction data were collected with 0.3° oscillations from randomly ori-
ented crystals on Fuji storage phosphor imaging plates. All crystals
were cooled to 4° C and the crystal-to-image plate distance was
360 mm. Exposure times were 15 to 30 s per oscillation image with a
typical crystal providing four to six useful images before decaying from
radiation damage. The crystals diffracted to at least 2.6 Å resolution.
The image plates were scanned using a BAS 2000 scanner with a
raster step of 100 mm. The digitized images were indexed, processed,
scaled, and postrefined using the HKL package [106]. A summary of
the data statistics is given in Table 1. The autoindexing of the images
using HKL gave one clear solution for the lattice type: C-centered
orthorhombic. The space group, C2221, was assigned based on the
systematic absences observed along 00l, where l = 2n+1. The postre-
fined unit cell dimensions are a = 345.7 Å, b = 497.2 Å, and c = 485.9 Å.
Assuming four particles per unit cell (Z = 4), the Matthew’s coefficient
(VM) would be 2.5 Å3/Da [107]. No other assumption is reasonable.
Therefore, the virus particle had to be situated on one of the twofold
axes of the unit cell, at either (x,0,0) or (0,y,1/4), as required by the
space group. Consequently, one asymmetric unit contains thirty pro-
tomers related by icosahedral symmetry.
Structure determination
The structure was determined by the molecular replacement method
using the programs GLRF [108] and X-PLOR [109]. A locked self-rota-
tion function search, using GLRF, gave a single clear solution indicat-
ing that the virus particle was rotated 54.8° about the twofold axis
along y (f = 0° , y = 0° , k = 54.8° ), relative to a standard orientation of
an icosahedron [108]. Cross-rotation function searches using PV1M
as the search model confirmed the self-rotation function interpretations
[39]. When the virus particle was rotated 54.8° about the y axis of the
unit cell, a one-dimensional translation search using X-PLOR yielded a
clear solution with the virus particle located at y = 0.191 (x = 0,
z = 0.25). Initial phases were calculated from the PV1M search model
and combined with the observed structure factors to generate an elec-
tron-density map. This initial map (R factor = 29.9% and correlation
coefficient (CC) = 0.738) was then averaged using the program RAVE
[110] utilizing the 30-fold NCS present in the crystals. The averaging
procedure used all data between 30 and 2.9 Å resolution (444,595
reflections). Upon convergence of the averaging, the agreement
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Figure 9
Plot of the averaging R factor (Rav; black triangles) and correlation
coefficient (CC; black squares) over the resolution range 30–2.9 Å.
Rav = S |( |Fobs|–|Fav|) |/ S |Fobs|X 100.
CC =S (<Fobs>–Fobs)(<Fav>–Fav)/[S (<Fobs>–Fobs)2S (<Fav>–Fav)2]1/2.
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between the observed data and those calculated from back-transfor-
mation of the averaged map was excellent: Rav = 12.9% and CC = 0.95
(Figure 9). The averaged map was of very high quality and the amino
acid substitutions between PV2L and PV1M were clearly evident in the
electron-density maps. The model was built into the averaged electron
density using the graphics program O [111].
Refinement
The model of PV2L was refined using conjugate-gradient minimization
as implemented in X-PLOR [109]. Strict noncrystallographic symmetry
(NCS) constraints were imposed throughout the refinement procedure.
This increased the data-to-parameter ratio by a factor of 30 so that there
were approximately 15 observations per parameter refined. The parame-
ters of Engh and Huber were used for restraining the protein structure
[112]. In the initial stages of refinement, no water molecules, antiviral
agent, or myristic acid moiety were included. After the model was rebuilt
and refined to an R factor of 25.8% for data between 10 and 2.9 Å reso-
lution, a difference map was generated using (Fo–Fc) amplitudes and
phases, f av, derived from the averaged electron-density map. The differ-
ence map was then averaged for one cycle utilizing the 30-fold NCS
and all data between 30 and 2.9 Å resolution. Clear electron density
corresponding to the SCH48973 antiviral agent was present in the dif-
ference map, as well as to many ordered water molecules.
Peaks were assigned as water molecules if they met the following crite-
ria: they were present in the difference electron-density map at a height
of at least 3s; and they had possible hydrogen-bonding partners from
either the viral proteins or other water molecules. At this stage, the antivi-
ral agent and myristate (up to C10) were included in the refinement. The
model for the SCH48973 antiviral agent was built using the program
Insight version 2.2.0 (Biosym Technologies Inc.). The SCH48973 para-
meter and topology files were generated using the program XPLO2D
and the three phenyl rings of the antiviral agent were restrained to be
planar [113]. The myristate was built (up to C10) using coordinates from
the myristate of PV1M [39]. The myristate parameter and topology files
were generated using the program XPLO2D [113]. In X-PLOR, a patch
was written to simulate covalent attachment of the myristate to the N-ter-
minal glycine of VP4, enabling restraint of the peptide bond. The final
step in the refinement procedure was the restrained refinement of indi-
vidual isotropic temperature factors (B factors).
Structure refinement of PV2L in complex with SCH48973 yielded an R
factor of 18.5% for 402,860 reflections with F > 2s (F) between 10 and
2.9Å resolution. In the presence of high NCS, there is a strong interde-
pendence of structure factors [74,114]. Therefore, no free R factor was
used to monitor the refinement procedure [115]. The geometry of the
model was monitored using the program PROCHECK [116]. The
Ramachandran plot shows that 98.9% of the residues lie in the allowed
regions. A summary of the refinement statistics is given in Table 1.
SCH48973 surface area calculations
The algorithm used for surface area calculations is that of Lee and
Richards using a spherical solvent probe with 1.4 Å radius [117]. The
total surface area buried upon complex formation is the sum of the
buried surface area of the antiviral agent and the buried protein
surface. The buried protein surface is the difference in the accessible
surface of the protomer in the presence and absence of antiviral agent,
with both of these calculations assuming the pocket conformation
observed in the complex.
Accession numbers
The coordinates and structure-factor amplitudes have been submitted
to the Brookhaven Protein Data Bank (PDB). Requests for the
PV2L–SCH48973 coordinates prior to release from the PDB can sent
via email to arnold@cabm.rutgers.edu. 
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